UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC

Cancer treatment reviews, 2014-04, Vol.40 (3), p.445-456

2014

Volltextzugriff (PDF)

Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature

PloS one, 2013-01, Vol.8 (1), p.e54193

2013

Volltextzugriff (PDF)

The Role of Inflammation in the Pathogenesis of Non-small Cell Lung Cancer

Journal of thoracic oncology, 2010-12, Vol.5 (12), p.2024-2036

2010

Volltextzugriff (PDF)

Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage

Nature communications, 2019-12, Vol.10 (1), p.5501-12, Article 5501

2019

Volltextzugriff (PDF)

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

The lancet oncology, 2012, Vol.13 (1), p.33-42

2012

Volltextzugriff (PDF)

The fructose-bisphosphate, Aldolase A (ALDOA), facilitates DNA-PKcs and ATM kinase activity to regulate DNA double-strand break repair

Scientific reports, 2023-09, Vol.13 (1), p.15171-14, Article 15171

2023

Volltextzugriff (PDF)

Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells

British journal of cancer, 2024-04, Vol.130 (7), p.1196-1205

2024

Volltextzugriff (PDF)

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

The lancet oncology, 2020-09, Vol.21 (9), p.1213-1223

2020

Volltextzugriff (PDF)

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

The lancet oncology, 2011-08, Vol.12 (8), p.795-805

2011

Volltextzugriff (PDF)

BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC

Cancer letters, 2018-08, Vol.428, p.117-126

2018

Volltextzugriff (PDF)

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

The lancet oncology, 2015-02, Vol.16 (2), p.141-151

2015

Volltextzugriff (PDF)

Human single-stranded DNA binding proteins are essential for maintaining genomic stability

BMC molecular biology, 2013-04, Vol.14 (1), p.9-9, Article 9

2013

Volltextzugriff (PDF)

The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer

Frontiers in oncology, 2018-08, Vol.8, p.311-311

2018

Volltextzugriff (PDF)

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2014-02, Vol.83 (2), p.211-218

2014

Volltextzugriff (PDF)

hSSB2 (NABP1) is required for the recruitment of RPA during the cellular response to DNA UV damage

Scientific reports, 2021-10, Vol.11 (1), p.20256-12, Article 20256

2021

Volltextzugriff (PDF)

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC

European journal of cancer (1990), 2024-09, Vol.208, p.114204, Article 114204

2024

Volltextzugriff (PDF)

An Exploration of Small Molecules That Bind Human Single-Stranded DNA Binding Protein 1

Biology (Basel, Switzerland), 2023-11, Vol.12 (11), p.1405

2023

Volltextzugriff (PDF)

Lung cancer stem cells: The root of resistance

Cancer letters, 2016-03, Vol.372 (2), p.147-156

2016

Volltextzugriff (PDF)

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells

Cancers, 2019-04, Vol.11 (4), p.548

2019

Volltextzugriff (PDF)

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Frontiers in oncology, 2018-03, Vol.8, p.92-92

2018

Volltextzugriff (PDF)

Drug Discovery Approaches Utilizing Three-Dimensional Cell Culture

Assay and drug development technologies, 2016-02, Vol.14 (1), p.19-28

2016

Volltextzugriff (PDF)

The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer

Frontiers in oncology, 2020-07, Vol.10, p.1256-1256

2020

Volltextzugriff (PDF)

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer

The European respiratory journal, 2015-12, Vol.46 (6), p.1762-1772

2015

Volltextzugriff (PDF)

1 – 25 von 296

Suche als RSS-Feed

Aktive Filter

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(271)
Mit Volltextzugriff
(274)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(192)
Life Sciences & Biomedicine
(175)
Humans
(147)
Oncology
(123)
Lung Cancer
(54)
Female
(52)
Male
(50)
Aged
(45)
Lung Neoplasms - Pathology
(45)
Middle Aged
(44)
Chemotherapy
(42)
Adult
(41)
Respiratory System
(41)
Lung Neoplasms - Drug Therapy
(39)
Tumors
(37)
Biological And Medical Sciences
(34)
Lung Neoplasms - Genetics
(34)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(32)
Cancer
(31)
Medical Sciences
(31)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Thoracic Oncology
(56)
Lung Cancer
(18)
Frontiers In Oncology
(10)
The Lancet Oncology
(10)
Clinical Lung Cancer
(8)
Plos One
(8)
Cancers
(7)
Asia-Pacific Journal Of Clinical Oncology
(6)
Scientific Reports
(6)
Bmc Molecular Biology
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC

Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature

The Role of Inflammation in the Pathogenesis of Non-small Cell Lung Cancer

Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

The fructose-bisphosphate, Aldolase A (ALDOA), facilitates DNA-PKcs and ATM kinase activity to regulate DNA double-strand break repair

Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Human single-stranded DNA binding proteins are essential for maintaining genomic stability

The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

hSSB2 (NABP1) is required for the recruitment of RPA during the cellular response to DNA UV damage

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC

An Exploration of Small Molecules That Bind Human Single-Stranded DNA Binding Protein 1

Lung cancer stem cells: The root of resistance

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Drug Discovery Approaches Utilizing Three-Dimensional Cell Culture

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer

Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer

Aktive Filter

Suchergebnisse filtern